Administration of FGF19 to obese mice or its overexpression has been reported to increase metabolic rate and improve obesity, hepatic steatosis, insulin sensitivity and plasma lipid levels (52, 53). Here, INS is linked to obesity due to melanocortin 4 receptor deficiency.